Twist Bioscience Corporation (TWST) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $17.04M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $12.13M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $59.70M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $17.04M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $17.04M |
| Deferred revenue · latest quarter (USD) | $12.13M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. $6.47M + $5.67M ≈ $12.13M |
| Other obligations · due within 1 year (USD) | $59.70M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $59.70M |
| Other obligations · due after 1 year (USD) | $6.48M | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. $6.48M − $0.00 ≈ $6.48M |
Calculation inputs
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $59.70M
- Other obligations · due after 1 year (USD)
- $6.48M
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $93.59M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $17.04M | $12.13M | $59.70M | $6.48M | $226.70M | (m) | $6.47M | $5.67M | $6.48M | $0.00 |
| 2026-03-31 | (m) | $14.68M | $7.09M | $67.85M | $746.00K | $221.12M | (m) | $7.09M | $0.00 | $746.00K | $0.00 |
| 2025-12-31 | (m) | $12.49M | $9.02M | $13.47M | $741.00K | $181.99M | (m) | $9.02M | $0.00 | $741.00K | $0.00 |
| 2025-09-30 | (m) | $11.09M | $6.88M | $12.15M | $747.00K | $168.90M | (m) | $6.88M | $0.00 | $747.00K | $0.00 |
| 2025-06-30 | (m) | $11.98M | $6.23M | $11.08M | $778.00K | $165.41M | (m) | $6.32M | $-90.00K | $688.00K | $-90.00K |
| 2025-03-31 | (m) | $8.06M | $1.99M | $7.21M | $1.13M | $155.51M | (m) | $2.66M | $-675.00K | $451.00K | $-675.00K |
| 2024-12-31 | (m) | $7.50M | $1.38M | $5.24M | $407.00K | $152.64M | (m) | $1.38M | $0.00 | $407.00K | $0.00 |
| 2024-09-30 | (m) | $1.63M | $2.13M | $5.82M | $407.00K | $141.63M | (m) | $2.13M | $0.00 | $407.00K | $0.00 |
| 2024-06-30 | (m) | $6.63M | $2.90M | $6.08M | $637.00K | $146.98M | (m) | $2.94M | $-40.00K | $597.00K | $-40.00K |
| 2024-03-31 | (m) | $7.70M | $2.50M | $5.44M | $463.00K | $142.72M | (m) | $2.54M | $-42.00K | $421.00K | $-42.00K |
| 2023-12-31 | (m) | $9.26M | $2.60M | $6.42M | $519.00K | $142.77M | (m) | $2.64M | $-44.00K | $475.00K | $-44.00K |
| 2023-09-30 | (m) | $14.05M | $3.00M | $7.80M | $474.00K | $152.97M | (m) | $3.00M | $1.00K | $475.00K | $1.00K |
| 2023-06-30 | (m) | $12.18M | $3.00M | $9.91M | $62.00K | $152.78M | (m) | $3.00M | $-2.00K | $60.00K | $-2.00K |
| 2023-03-31 | (m) | $13.24M | $1.90M | $10.04M | $104.00K | $149.99M | (m) | $1.94M | $-44.00K | $60.00K | $-44.00K |
| 2022-12-31 | (m) | $20.11M | (m) | $15.82M | (m) | $163.65M | (m) | $3.68M | (m) | $60.00K | (m) |
| 2022-09-30 | (m) | $20.09M | $3.50M | $19.74M | $36.00K | $171.99M | (m) | $3.48M | $24.00K | $60.00K | $24.00K |
| 2022-06-30 | (m) | $21.01M | (m) | $20.12M | (m) | $158.99M | (m) | (m) | (m) | $2.06M | (m) |
| 2022-03-31 | (m) | $16.82M | (m) | $16.02M | (m) | $158.28M | (m) | (m) | (m) | $8.15M | (m) |
| 2021-12-31 | (m) | $23.07M | (m) | $13.86M | (m) | $159.99M | (m) | (m) | (m) | $19.67M | (m) |
| 2021-09-30 | (m) | $14.90M | $1.10M | $9.62M | (m) | $121.28M | (m) | (m) | (m) | $5.07M | (m) |
| 2021-06-30 | (m) | $11.27M | (m) | $9.27M | (m) | $114.85M | (m) | (m) | (m) | $6.17M | (m) |
| 2021-03-31 | (m) | $8.53M | (m) | $4.06M | (m) | $63.11M | (m) | $600.00K | (m) | $422.00K | (m) |
| 2020-12-31 | (m) | $8.93M | (m) | $3.31M | (m) | $61.62M | (m) | (m) | (m) | $210.00K | (m) |
| 2020-09-30 | (m) | $4.83M | $0.00 | $2.61M | (m) | $62.62M | (m) | (m) | (m) | $351.00K | (m) |
| 2020-06-30 | (m) | $5.97M | (m) | $1.37M | (m) | $59.29M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $6.93M | (m) | $52.00K | (m) | $59.67M | (m) | (m) | (m) | $95.00K | (m) |
| 2019-12-31 | (m) | $9.11M | (m) | $999.00K | (m) | $89.20M | (m) | (m) | (m) | $144.00K | (m) |
| 2019-09-30 | (m) | $9.76M | $0.00 | $817.00K | (m) | $34.91M | (m) | (m) | (m) | $158.00K | (m) |
| 2019-06-30 | (m) | $7.83M | (m) | $680.00K | (m) | $30.80M | (m) | (m) | (m) | $236.00K | (m) |
| 2019-03-31 | (m) | $4.50M | (m) | $894.00K | (m) | $24.69M | (m) | (m) | (m) | $282.00K | (m) |
| 2018-12-31 | (m) | $6.72M | (m) | $1.07M | (m) | $25.86M | (m) | (m) | (m) | $333.00K | (m) |
| 2018-09-30 | (m) | $7.53M | (m) | $939.00K | (m) | $26.73M | (m) | (m) | (m) | $344.00K | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |